The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Abstract
CONTEXT: Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (Abeta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of Abeta correlates with dementia and whether Abeta alterations precede or follow changes in tau. OBJECTIVES: To determine whether accumulation of Abeta correlates with the earliest signs of cognitive deterioration and to define the relationship between Abeta accumulation and early tau changes. DESIGN, SETTING, AND PATIENTS: Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of Abeta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia. MAIN OUTCOME MEASURES: Levels of total Abeta peptides with intact or truncated amino termini and ending in either amino acid 40 (A(beta)x-40) or 42 (A(beta)x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score. RESULTS: The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia. Levels of the more fibril-prone A(beta)x-42 peptide were higher than those of A(beta)x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease. CONCLUSIONS: In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology. These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The accumulation of Aβ has been suggested to prompt neurodegeneration, thereby leading to the clinical dementia often witnessed in AD patients [15].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [15]
In the citing paper
“biochemical studies on human AD brain indicated that the soluble pool of Aβ42 correlated best with degree of cognitive loss [108, 118, 130].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [130]
In the citing paper
“Studies have increasingly differentiated between soluble and insoluble pools of Aβ within the brain, where it is the increase in the soluble pool of Aβ42 that tracks best with cognitive decline in AD [108, 118, 130].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [130]
Citations
Cites
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Yankner, B. A. (1996) · Neuron · doi:10.1016/s0896-6273(00)80115-4 · Cited by 953
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 879
Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide
Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 686
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Bierer, L. M., Haroutunian, V. H., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P. D., & Davis, K. L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020749.x · Cited by 580
Cited by
Sorted by citations
Items 301–400 of 1,000
Pasinetti, G. M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1176 · Cited by 111
Quantitative MR Imaging in Alzheimer Disease
Ramani, A., Jensen, J. H., & Helpern, J. A. (2006) · Radiology · doi:10.1148/radiol.2411050628 · Cited by 113
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
A critical analysis of the ‘amyloid cascade hypothesis’
A. Armstrong, R. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45562 · Cited by 110
Transgenic Drosophila models of Alzheimer’s disease and tauopathies
Iijima‐Ando, K., & Iijima, K. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0234-4 · Cited by 118
The brain RAS and Alzheimer's disease
Wright, J. W., & Harding, J. W. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.012 · Cited by 113
Role of the Immune System in the Pathogenesis, Prevention and Treatment of Alzheimer??s Disease
Blasko, I., & Grubeck-Loebenstein, B. (2003) · Drugs & Aging · doi:10.2165/00002512-200320020-00002 · Cited by 108
Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108
Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate
Mamelak, M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.008 · Cited by 108
Molecules that Target beta‐Amyloid
Stains, C. I., Mondal, K., & Ghosh, I. (2007) · ChemMedChem · doi:10.1002/cmdc.200700140 · Cited by 113
Bussière, T., Friend, P. D., Sadeghi, N., Wicinski, B. A., Lin, G. I., Bouras, C., Giannakopoulos, P., Robakis, N. K. R. K., Morrison, J. H., Perl, D. P., et al. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00056-8 · Cited by 108
Almeida, R. P., Schultz, S. A., Austin, B. P., Boots, E. A., Dowling, N. M., Gleason, C. E., Bendlin, B. B., Sager, M. A., Hermann, B. P., Zetterberg, H., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0098 · Cited by 107
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P. J., Multhaup, G., Brody, D. L., Esparza, T., Ingelsson, M., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0314-x · Cited by 106
Cahill‐Smith, S., & Li, J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12357 · Cited by 109
The unsolved relationship of brain aging and late-onset Alzheimer disease
Kern, A., & Behl, C. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.016 · Cited by 108
Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice
Dineley, K. T., Kayed, R., Neugebauer, V., Fu, Y., Zhang, W., Reese, L. C., & Taglialatela, G. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22445 · Cited by 110
Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Magnusson, K., Sehlin, D., Syvänen, S., Svedberg, M. M., Philipson, O., Söderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Максимилианович, Т. В., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130029 · Cited by 107
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000016 · Cited by 106
The effects of cholesterol on learning and memory
Schreurs, B. G. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.010 · Cited by 114
Distinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain: A Clinicopathologic Study
Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B., & Stern, Y. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.906 · Cited by 104
Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Metal binding sites in amyloid oligomers: Complexes and mechanisms
Miller, Y., Ma, B., & Nussinov, R. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2011.12.022 · Cited by 103
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Age‐dependent impairment of glucose tolerance in the 3xTg‐AD mouse model of Alzheimer's disease
Vandal, M., White, P. J., Chevrier, G., Tremblay, C., St‐Amour, I., Planel, E., Marette, A., & Calon, F. (2015) · The FASEB Journal · doi:10.1096/fj.14-268482 · Cited by 107
A Sensitive and Quantitative Assay for Measuring Cleavage of Presenilin Substrates
Karlström, H., Bergman, A., Lendahl, U., Näslund, J., & Lundkvist, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100649200 · Cited by 103
Self-citationThe Development of Anti-Amyloid Therapy for Alzheimer???s Disease
Aisen, P. S. S. (2005) · CNS Drugs · doi:10.2165/00023210-200519120-00002 · Cited by 103
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelová, P., Růžička, J., Urdzíková, L. M., & Syková, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 110
Wang, H.-Y., Stucky, A., Liu, J., Shen, C., Trocmé, C., & Morain, P. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6088-08.2009 · Cited by 102
Higaki, S., Muramatsu, M., Matsuda, A., Matsumoto, K., Satoh, J., Michikawa, M., & Niida, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196929 · Cited by 103
Sankaranarayanan, S., Price, E. A., Wu, G., Crouthamel, M., Shi, X., Tugusheva, K., Tyler, K. X., Kahana, J. A., Ellis, J. D., Jin, L., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130039 · Cited by 101
Ciccotosto, G. D., Tew, D. J., Curtain, C. C., Smith, D., Carrington, D., Masters, C. L., Bush, A. I., Cherny, R. A., Cappai, R., & Barnham, K. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406465200 · Cited by 101
Alberdi, E. M., Sánchez‐Gómez, M. V., Ruiz, A., Cavaliere, F., Ortiz-Sanz, C., Quintela‐López, T., Capetillo‐Zarate, E., Solé‐Domènech, S., & Matute, C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2856063 · Cited by 102
Oikawa, N., Kimura, N., & Yanagisawa, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.12.005 · Cited by 101
Zhang, C., Zheng, X., Xu, W., Shao, X., Liu, Q., Zhang, Z., & Zhang, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.050 · Cited by 102
Poon, W. W., Carlos, A. J., Aguilar, B. L., Berchtold, N. C., Kawano, C. K., Zograbyan, V., Yaopruke, T., Shelanski, M. L., & Cotman, C. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463711 · Cited by 101
Styrylbenzoxazole Derivatives forIn VivoImaging of Amyloid Plaques in the Brain
Okamura, N., Suemoto, T., Shimadzu, H., Suzuki, M., Shiomitsu, T., Akatsu, H., Yamamoto, T., Staufenbiel, M., Yanai, K., Arai, H., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4456-03.2004 · Cited by 100
Elevated Plasma β-Amyloid Peptide Aβ42 Levels, Incident Dementia, and Mortality in Down Syndrome
Schupf, N., Patel, B. N., Pang, D. I., Zigman, W. B., Silverman, W. P., Mehta, P. D., & Mayeux, R. P. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.1007 · Cited by 102
Immunotherapy for Alzheimer's disease
Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 103
Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
Caselli, R. J., Dueck, A. C., Locke, D. E. C., Hoffman‐Snyder, C. R., Woodruff, B. K., Rapcsak, S. Z., & Reiman, E. M. (2011) · Neurology · doi:10.1212/wnl.0b013e3182167147 · Cited by 105
Chapter 4 Alzheimer's Disease in Adults with Down Syndrome
Zigman, W. B., Devenny, D. A., Krinsky‐McHale, S. J., Jenkins, E. C., Urv, T. K., Węgiel, J., Schupf, N., & Silverman, W. P. (2008) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)00004-9 · Cited by 106
Behavior of neural stem cells in the Alzheimer brain
Waldau, B., & Shetty, A. K. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8053-y · Cited by 101
Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Cc, R., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 101
Active γ‐secretase is localized to detergent‐resistant membranes in human brain
Hur, J., Welander, H., Behbahani, H., Aoki, M., Frånberg, J., Winblad, B. G., Frykman, S., & Tjernberg, L. O. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06278.x · Cited by 100
Corey‐Bloom, J. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008664 · Cited by 97
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Villemagne, V. L., Fodero‐Tavoletti, M. T., Pike, K. E., Cappai, R., Masters, C. L., & Rowe, C. C. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8019-y · Cited by 103
Best, J. D., Jay, M. T., Otu, F., Ma, J., Nadin, A. J., Ellis, S., Lewis, H. D., Pattison, C., Reilly, M., Harrison, T., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081174 · Cited by 98
Maruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Higuchi, S., Matsushita, S., Yoshida, H., et al. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7814 · Cited by 97
Friedhoff, L. T., Cullen, E. I., Geoghagen, N. S. M., & Buxbaum, J. D. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002310 · Cited by 97
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography
Klunk, W. E., Engler, H., Nordberg, A., Bacskai, B. J., Wang, Y., Price, J. C., Bergström, M., Hyman, B. T., Långström, B., & Mathis, C. A. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00092-3 · Cited by 96
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 100
Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman
Selkoe, D. J. (2003) · Neurochemical Research · doi:10.1023/a:1026065122854 · Cited by 98
Neuronal LR11/sorLA expression is reduced in mild cognitive impairment
Sager, K. L., Wuu, J., Leurgans, S. E., Rees, H. D., Gearing, M., Mufson, E. J., Levey, A. I., & Lah, J. J. (2007) · Annals of Neurology · doi:10.1002/ana.21190 · Cited by 96
Lima, M. G. P., Schimidt, H. L., Garcia, A., Daré, L. R., Carpes, F. P., Izquierdo, I., & Mello‐Carpes, P. B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718435115 · Cited by 95
Giannakopoulos, P., Gold, G., Kövari, E., von Gunten, A., Imhof, A., Bouras, C., & Hof, P. R. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0144-y · Cited by 96
ApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Selkoe, D. J. (2000) · Nature Biotechnology · doi:10.1038/78422 · Cited by 94
Tremblay, C., St‐Amour, I., Schneider, J. A., Bennett, D. A., & Calon, F. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822c62cf · Cited by 98
Zhang, W., Hao, J., Liu, R., Zhang, Z., Lei, G., Su, C., Miao, J., & Li, Z. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.072 · Cited by 100
Long-term prognosis and educational determinants of brain network decline in older adult individuals
Chan, M. Y., Han, L., Carreno, C. A., Zhang, Z., Rodriguez-Boerwinkle, R. M., LaRose, M., Hassenstab, J. J., & Wig, G. S. (2021) · Nature Aging · doi:10.1038/s43587-021-00125-4 · Cited by 102
Mild cognitive impairment: Conceptual issues and structural and functional brain correlates
Saykin, A. J., & Wishart, H. A. (2003) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2003.50002 · Cited by 93
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET
Grimmer, T., Henriksen, G., Wester, H., Förstl, H., Klunk, W. E., Mathis, C. A., Kurz, A., & Drzezga, A. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.016 · Cited by 96
Ibuprofen Decreases Cytokine-Induced Amyloid Beta Production in Neuronal Cells
Blasko, I., Apochal, A., Boeck, G., Hartmann, T., Grubeck‐Loebenstein, B., & Ransmayr, G. N. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0451 · Cited by 92
Aβ Internalization by Neurons and Glia
Mohamed, A., & Chaves, E. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/127984 · Cited by 94
Vazin, T., Ball, K. A., Lü, H., Park, H., Ataeijannati, Y., Head-Gordon, T. L., Poo, M., & Schaffer, D. V. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.005 · Cited by 94
Bouter, Y., Kacprowski, T., Weissmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00075 · Cited by 76
Pasinetti, G. M. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00091-7 · Cited by 91
Treatment of Alzheimer’s Disease with a Cholinesterase Inhibitor Combined with Antioxidants
Cornelli, U. (2010) · Neurodegenerative Diseases · doi:10.1159/000295663 · Cited by 90
Correlation Between Aβx-40–, Aβx-42–, and Aβx-43–Containing Amyloid Plaques and Cognitive Decline
Parvathy, S., Davies, P., Haroutunian, V. H., Purohit, D. P., Davis, K. L., Mohs, R. C., Park, H., Moran, T. M., Chan, J. Y., & Buxbaum, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.2025 · Cited by 90
Guercio, B. J., Donovan, N. J., Munro, C. E., Aghjayan, S. L., Wigman, S. E., Locascio, J. J., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150146 · Cited by 98
Amyloid imaging in Alzheimer's disease
Nordberg, A. K. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.03.020 · Cited by 92
Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.
Horikoshi, Y., Sakaguchi, G., Becker, A. G., Gray, A. J., Duff, K., Aisen, P., Yamaguchi, H., Maeda, M., Kinoshita, N., & Matsuoka, Y. (2004) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2004.05.051 · Cited by 95
APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0539-7 · Cited by 87
β‐Site APP‐cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis
Tan, J., & Evin, G. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07623.x · Cited by 90
Clark, J. K., Furgerson, M., Crystal, J. D., Fechheimer, M., Furukawa, R., & Wagner, J. J. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.09.003 · Cited by 92
Simvastatin therapy prevents brain trauma‐induced increases in β‐amyloid peptide levels
Abrahamson, E. E., Ikonomović, M. D., Dixon, C. E., & DeKosky, S. T. (2009) · Annals of Neurology · doi:10.1002/ana.21731 · Cited by 89
Tau protein abnormalities associated with the progression of alzheimer disease type dementia
Haroutunian, V., Davies, P., Vianna, C., Buxbaum, J. D., & Purohit, D. P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.11.001 · Cited by 86
He, Y., Zheng, M., Ma, Y., Han, X., Ma, X.-Q., Qu, C., & Du, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.129 · Cited by 91
Sokolow, S., Luu, S. H., Nandy, K., Miller, C. A., Vinters, H. V., Poon, W. W., & Gylys, K. H. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.027 · Cited by 90
Neurogenesis in mouse models of Alzheimer's disease
Chuang, T. T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.008 · Cited by 88
Canas, P. M., Simões, A. P., Rodrigues, R. J., & Cunha, R. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.026 · Cited by 86
Curcuminoid Binds to Amyloid-β1-42 Oligomer and Fibril
Yanagisawa, D., Taguchi, H., Yamamoto, A., Shirai, N., Hirao, K., & Tooyama, I. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102100 · Cited by 85
Richardson, J. C., Kendal, C., Anderson, R., Priest, F., Gower, E., Soden, P. E., Gray, R., Topps, S., Howlett, D. R., Lavender, D., et al. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00389-0 · Cited by 85
Tian, L., Guo, R., Yue, X., Lv, Q., Ye, X., Wang, Z., Chen, Z., Wu, B., Xu, G., & Liu, X. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.059 · Cited by 84
Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice
Chauhan, N. B., & Sandoval, J. (2007) · Phytotherapy Research · doi:10.1002/ptr.2122 · Cited by 86
Amyloid load in nondemented brains correlates with APOE e4
Caselli, R. J., Walker, D. G., Sue, L. I., Sabbagh, M. N., & Beach, T. G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.016 · Cited by 85
Wood, L. B., Winslow, A. R., Proctor, E. A., McGuone, D., Mordes, D. A., Frosch, M. P., Hyman, B. T., Lauffenburger, D. A., & Haigis, K. M. (2015) · Scientific Reports · doi:10.1038/srep16622 · Cited by 83
Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients
Hellström‐Lindahl, E., Mousavi, M. T., Ravid, R., & Nordberg, A. K. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.11.024 · Cited by 83
β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Andreasen, N., & Blennow, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00056-6 · Cited by 86
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1–42
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Blaine Stine, W., Manelli, A., Sullivan, P., Pasternak, J. F., & LaDu, M. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.011 · Cited by 82
Tian, Y., Tang, F.-L., Sun, X., Wen, L., Mei, L., Tang, B.-S., & Xiong, W.-C. (2015) · Molecular Brain · doi:10.1186/s13041-015-0156-4 · Cited by 76
The protective role of plant biophenols in mechanisms of Alzheimer's disease
Omar, S. H., Scott, C., Hamlin, A. S., & Obied, H. K. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.02.016 · Cited by 84
Narayan, P. S., Ganzinger, K. A., McColl, J. T., Weimann, L., Meehan, S., Qamar, S., Carver, J. A., Wilson, M. R., George‐Hyslop, P. S., Dobson, C. M., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3103567 · Cited by 85
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide
Ashur‐Fabian, O., Segal-Ruder, Y., Skutelsky, E., Brenneman, D. E., Steingart, R. A., Giladi, E., & Gozes, I. (2003) · Peptides · doi:10.1016/j.peptides.2003.08.005 · Cited by 83
Rudnitskaya, E. A., Muraleva, N. A., Maksimova, K. Y., Владимировна, К. Е., Kolosova, N. G., & Stefanova, N. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150161 · Cited by 82
Buxbaum, J. D. (2002) · Frontiers in bioscience · doi:10.2741/a739 · Cited by 82
Neuroserpin Binds Aβ and Is a Neuroprotective Component of Amyloid Plaques in Alzheimer Disease
Kinghorn, K. J., Crowther, D. C., Sharp, L. K., Nerelius, C., Davis, R. L., Chang, H. T., Green, C. K., Gubb, D., Johansson, J., & Lomas, D. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600690200 · Cited by 81
Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein
Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201308200 · Cited by 86
GSK3 and p53 - is there a link in Alzheimer's disease?
Proctor, C. J., & Gray, D. A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-7 · Cited by 80
Amyloid-β Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines
Head, E., Pop, V., Sarsoza, F. M., Kayed, R., Beckett, T. L., Studzinski, C. M., Tomic, J. L., Glabe, C. G., & Murphy, M. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1397 · Cited by 84
Metadata
- Authors
- Näslund, J.
- Affiliations
- Rockefeller University (US)
- Corresponding author
- Näslund, Jan
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-03-22
- Volume
- 283
- Issue
- 12
- Pages
- 1571
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2000706612
- Cited by
- 1,268
- References
- 28
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 32 · 2023: 23 · 2022: 28 · 2021: 32 · 2020: 31 · 2019: 29 · 2018: 34 · 2017: 29 · 2016: 57 · 2015: 56 · 2014: 60 · 2013: 59 · 2012: 65
- FWCI
- 40.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-02219, AG 05138, P50AG005138, AG 14996, P01AG002219)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, cognitive decline, dementia progression, tau protein, amyloid-beta 42, Aβ40, frontal cortex, Clinical Dementia Rating, postmortem brain, neocortex, nursing home residents, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Aged, Aged, 80 and over, Brain, Cognition Disorders, Cross-Sectional Studies, Dementia, Enzyme-Linked Immunosorbent Assay, Female, Frontal Lobe, Humans, Immunoenzyme Techniques, Male, Immunoblotting, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
